SynthesisPloS one2015

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Luisa Carbognin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.